[Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost].
Radiocontrast nephropathy (RCN) is a major complication after radiographical examination with iodinated contrast media (CM). Although little is known about the mechanism of RCN, a direct toxic action on renal cells and/or decrease in renal blood flow are considered to be implicated in the pathogenesis of the disease/the condition, A large number of vasodilatory agents, including endothelin antagonists, adenosine antagonists, atrial natriuretic peptide, calcium channel blockers, dopamine, dopamine D1 receptor agonist fenoldopam, and prostaglandin E1 have been tried clinically to prevent RCN, however, most of them have failed. Although prophylactic effects of antioxidant N-acetylcysteine have recently been reported by several investigators, only hydration is a universally accepted protocol to prevent it. In our recent in vitro and in vivo study, we have elucidated that CM induced apoptosis of renal tubular cells through the reduction in Bcl-2 expression and the subsequent activation of caspase-9 and caspase-3. Moreover, we found that CM caused an increase in ceramide content in renal tubular cells, which leads to apoptosis by inhibiting the phosphorylation of Akt and cAMP responsive element binding protein (CREB) and the subsequent reduction in Bcl-2 expression. The inhibitor of ceramide synthase, fumonisin B1, reversed both the elevation of ceramide content and renal cell injury induced by CM. On the other hand, a prostacyclin analog beraprost prevented RCN in mice by the increase of endogenous cAMP and subsequent CREB phosphorylation resulted in enhancement of Bcl-2 expression. These findings suggest that ceramide synthesis inhibitor or beraprost is potentially useful for the prophylaxis of RCN.
Yano
Takahisa
T
Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan. tyano@pharm.med.kyushu-u.ac.jp
D000111:Acetylcysteine / Q000008:administration & dosage; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002518:Ceramides / Q000378:metabolism; D003287:Contrast Media / Q000009:adverse effects / Q000633:toxicity*; D017362:Cyclic AMP Response Element-Binding Protein; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D011464:Epoprostenol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D037341:Fumonisins / Q000008:administration & dosage; D006801:Humans; D017613:Iodine Compounds / Q000009:adverse effects / Q000633:toxicity*; D007674:Kidney Diseases / Q000139:chemically induced* / Q000517:prevention & control*; D007684:Kidney Tubules / Q000166:cytology / Q000378:metabolism; D051379:Mice; D010766:Phosphorylation; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism
D002518:Ceramides; D003287:Contrast Media; D017362:Cyclic AMP Response Element-Binding Protein; D004791:Enzyme Inhibitors; D037341:Fumonisins; D017613:Iodine Compounds; D019253:Proto-Oncogene Proteins c-bcl-2; C048081:beraprost; C056933:fumonisin B1; D011464:Epoprostenol; D000111:Acetylcysteine